866-997-4948(US-Canada Toll Free)

Global Orphan Drugs Market 2017-2021

Published By :


Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 70 Pages

About Orphan Drugs

According to Orphan Drug Designation program of the US Food and Drug Administration (FDA), orphan diseases are defined as rare diseases that affects less than 2,00,000 Americans. The global orphan drugs market is expected to benefit from patent extensions like Orphan Drug Exclusivity (ODE), increasing focus of vendors on orphan drug products, and financial incentives provided by government in form of tax credits and waived FDA fees. For instance, the FDA grants a seven-year patent exclusivity to orphan drugs to treat a rare disease. Therefore, any other drug with the same indication cannot be approved by the FDA during these seven-years period. In addition, they also provide tax credits up to 50% of the total R&D cost after the drug receives the orphan drug designation. This credit can be used by the sponsor during the R&D phase of any drug irrespective of the drug designation. The orphan designated drugs are also exempted from paying the FDA fees. Thus, these financial incentives and grants for orphan drug attract many vendors to invest in developing drugs for rare diseases and make huge profits.

Technavios analysts forecast the global orphan drugs market to grow at a CAGR of 10.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global orphan drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

Technavio's report, Global Orphan Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffmann La Roche

Other prominent vendors
Alexion Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Novo Nordisk
Teva pharmaceutical

Market driver
Large growth opportunities through orphan drug designation.
For a full, detailed list, view our report

Market challenge
Costly treatment regimen results in financial burden on patients.
For a full, detailed list, view our report

Market trend
Emerging application for orphan drug development.
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Key market highlights
Pipeline analysis
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Regulatory approval
Orphan drug legislation
PART 07: Market segmentation by product type
PART 08: Geographical segmentation
Orphan drugs market in Americas
Orphan drugs market in EMEA
Orphan Drugs Market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market Drivers
Impact of drivers on key customer segments
Market Challenges
Impact of challenges on key customer segments
PART 11: Market trends
Emerging applications for orphan drug development
Increasing focus on development of biologics
Repurposing of non-orphan drugs to orphan drugs
PART 12: Competitive Scenario
Vendor landscape
PART 13: Key vendor analysis
F. Hoffmann La Roche
Other prominent vendors
PART 14: Appendix
List of Abbreviations
List of Exhibits
Exhibit 01: Overview of phase III molecules for few vendors
Exhibit 02: Pipeline overview based on different therapies
Exhibit 03: Pipeline analysis
Exhibit 04: Global orphan drugs market snapshot
Exhibit 05: Orphan drug requests' year-over-year growth 2014-2016
Exhibit 06: Few breakthroughs in global orphan drugs market 2014-2016
Exhibit 07: Global orphan drugs market 2016-2021 ($ billions)
Exhibit 08: Opportunity analysis in global orphan drugs market
Exhibit 09: Five forces analysis
Exhibit 10: Global orphan drugs market segmentation based on product type
Exhibit 11: Increasing trend of approval of biologics
Exhibit 12: Global orphan drugs market for biologics 2016-2021 ($ billions)
Exhibit 13: Few significant non-biologics approved as orphan drugs
Exhibit 14: Global orphan drugs market for non-biologics 2016-2021 ($ billions)
Exhibit 15: Global orphan drugs market by geography 2016 and 2021
Exhibit 16: Global orphan drugs market by geography 2016-2021 ($ billions)
Exhibit 17: Global orphan drugs market share by geography 2016-2021
Exhibit 18: Market Scenario in Americas
Exhibit 19: Orphan drugs market in Americas 2016-2021 ($ billions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Orphan drugs market in EMEA 2016-2021 ($ billions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Orphan drugs market in APAC 2016-2021 ($ billions)
Exhibit 24: Increase in FDA approval of orphan drugs 2012-2015
Exhibit 25: List of few benefits through orphan drug designation
Exhibit 26: Impact of drivers
Exhibit 27: Current pricing scenario of orphan drugs
Exhibit 28: Impact of challenges
Exhibit 29: Successful examples of repurposed blockbuster orphan drugs
Exhibit 30: Competitive structure analysis of global orphan drugs market 2016
Exhibit 31: Competitive analysis of global orphan drugs market
Exhibit 32: AbbVie: Key highlights
Exhibit 33: AbbVie: Key orphan drugs
Exhibit 34: AbbVie: Strength assessment
Exhibit 35: AbbVie: Strategy assessment
Exhibit 36: AbbVie: Opportunity assessment
Exhibit 37: Celgene: Key highlights
Exhibit 38: Celgene: Key orphan drugs
Exhibit 39: Celgene: Strength assessment
Exhibit 40: Celgene: Strategy assessment
Exhibit 41: Celgene: Opportunity assessment
Exhibit 42: Roche: Key highlights
Exhibit 43: Roche: Key orphan drugs
Exhibit 44: Roche: Strength assessment
Exhibit 45: Roche: Strategy assessment
Exhibit 46: Roche: Opportunity assessment
Exhibit 47: Novartis: Key highlights
Exhibit 48: Novartis: Key orphan drugs
Exhibit 49: Novartis: Strength assessment
Exhibit 50: Novartis: Strategy assessment
Exhibit 51: Novartis: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *